

1 **Word count:2680**

2

3 **COVID-19 clinical characteristics, and sex-specific risk of mortality: Systematic Review**  
4 **and Meta-analysis**

5

6 Mohammad Javad Nasiri \*

7 Department of Microbiology,

8 School of Medicine, Shahid Beheshti University of Medical Sciences,

9 Tehran, Iran

10 [mj.nasiri@hotmail.com](mailto:mj.nasiri@hotmail.com)

11

12 Sara Haddadi\*

13 Department of Pulmonary and Critical Care

14 University of Miami Miller School of Medicine

15 Miami, FL, USA.

16 [sxh1241@miami.edu](mailto:sxh1241@miami.edu)

17

18 Azin Tahvildari\*\*

19 School of Medicine, Shahid Beheshti University of Medical Sciences,

20 Tehran, Iran,

21 m.sina.h.2015@gmail.com

22

23 Yeganeh Farsi\*\*

24 School of Medicine, Shahid Beheshti University of Medical Sciences,

25 Tehran, Iran

26 Yeganehfarsi@yahoo.com

27

28 Mahta Arbabi\*\*

29 School of Medicine, Shahid Beheshti University of Medical Sciences,

30 Tehran, Iran.

31 arbabimahta24@gmail.com

32

33 Saba Hasanzadeh\*\*

34 School of Medicine, Shahid Beheshti University of Medical Sciences,

35 Tehran, Iran.

36 [hasanzadehsaba@yahoo.com](mailto:hasanzadehsaba@yahoo.com)

37

38 Parnian Jamshidi\*\*

39 School of Medicine, Shahid Beheshti University of Medical Sciences,

40 Tehran, Iran.

41 [parnian.jamshidi7@gmail.com](mailto:parnian.jamshidi7@gmail.com)

42

43 Mukunthan Murthi, MD\*\*

44 Department of Pulmonary and Critical Care

45 University of Miami Miller School of Medicine

46 Miami, FL, USA

47 [mxm193278@miami.edu](mailto:mxm193278@miami.edu)

48

49 Mehdi S. Mirsaeidi, MD, MPH

50 Department of Pulmonary and Critical Care

51 University of Miami Miller School of Medicine

52 Miami VA medical center

53 Miami, FL, USA.

54 [Msm249@med.miami.edu](mailto:Msm249@med.miami.edu)

55

56 • \*Should be consider as first authors.

57 • \*\*Equally contributed

58

59

60 **Corresponding author:**

61 Mehdi Mirsaeidi MD, MPH

62 Email: [msm249@med.miami.edu](mailto:msm249@med.miami.edu)

63

64 **Author contribution and guarantor information:**

65 Conception and design of study: Mohammad Nasiri, Mehdi Mirsaeidi

66 Acquisition of data: Azin Tahvildari, Yeganeh Farsi, Mahta Arbabi, Saba Hasanzadeh, Parnian

67 Jamshidi, Mohammad Nasiri

68 Analysis and/or interpretation of data: Mohammad Nasiri, Mehdi Mirsaeidi

69 Drafting and revision of manuscript: Sara Haddadi, Mukunthan Murthi, Mohamad Nasiri, Mehdi

70 Mirsaeidi

71 **Copyright/license for publication:**

72 "The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf  
73 of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms,  
74 formats and media (whether known now or created in the future), to i) publish, reproduce,  
75 distribute, display and store the Contribution, ii) translate the Contribution into other languages,  
76 create adaptations, reprints, include within collections and create summaries, extracts and/or,  
77 abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution,  
78 iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the  
79 Contribution to third party material where-ever it may be located; and, vi) licence any third party  
80 to do any or all of the above."

81

82 **Conflicts of interests:**

83 The authors do not have any conflicts of interest to declare.

84

85 All authors have completed the ICMJE uniform disclosure form at  
86 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: no support from any organisation for the submitted  
87 work; no financial relationships with any organisations that might have an interest in the submitted  
88 work in the previous three years; no other relationships or activities that could appear to have  
89 influenced the submitted work.

90

91 **Transparency statement:**

92 The lead author affirms that the manuscript is an honest, accurate, and transparent account of  
93 the study being reported; that no important aspects of the study have been omitted; and that any  
94 discrepancies from the study as originally planned (and, if relevant, registered) have been  
95 explained.

96

97 **Financial statement:**

98 The author(s) received no specific funding for this study.

99

100 **Dissemination declaration:**

101 Dissemination to results to the study participants and or patient organisations is not  
102 possible/applicable.

103

104

105

106

107 **Abstract:**

108 **Objectives:** The rapidly evolving coronavirus disease 2019 (COVID-19), was declared a  
109 pandemic by the World Health Organization on March 11, 2020. It was first detected in the city of  
110 Wuhan in China and has spread globally resulting in substantial health and economic crisis in  
111 many countries. Observational studies have partially identified the different aspects of this  
112 disease. Up to this date, no comprehensive systematic review for the clinical, laboratory,  
113 epidemiologic and mortality findings has been published. We conducted this systematic review  
114 and meta-analysis for a better understanding of COVID-19.

115 **Methods:** We reviewed the scientific literature published from January 1, 2019 to March 3, 2020.  
116 Statistical analyses were performed with STATA (version 14, IC; Stata Corporation, College  
117 Station, TX, USA). The pooled frequency with 95% confidence intervals (CI) was assessed using  
118 random effect model. Publication bias was assessed and  $p < 0.05$  was considered a statistically  
119 significant publication bias.

120 **Results:** Out of 1102 studies, 32 satisfied the inclusion criteria. A total of 4789 patients with a  
121 mean age of 49 years were evaluated. Fever (83.0%, CI 77.5 to 87.6), cough (65.2%, CI 58.6 to  
122 71.2) and myalgia/fatigue (34.7, CI 26.0 to 44.4) were the most common symptoms. The most  
123 prevalent comorbidities were hypertension (18.5 %, CI 12.7 to 24.4) and Cardiovascular disease  
124 (14.9 %, CI 6.0 to 23.8). Among the laboratory abnormalities, elevated C-Reactive Protein (CRP)  
125 (72.0% (CI 54.3 to 84.6) and lymphopenia (50.1%, CI 38.0 to 62.4) were the most common  
126 findings. Bilateral ground-glass opacities (66.0%, CI 51.1 to 78.0) was the most common CT-Scan

127 presentation. Pooled mortality rate was 6.6%, with males having significantly higher mortality  
128 compared to females (OR 3.4; 95% CI 1.2 to 9.1, P=0.01).

129 **Conclusion:** COVID-19 commonly presented with a progressive course of cough and fever with  
130 more than half of hospitalized patients showing leukopenia or a high CRP on their laboratory  
131 findings. Mortality associated with COVID19 was higher than that reported in studies in China  
132 with Males having a 3-fold higher risk of mortality in COVID19 compared to females.

133

#### 134 **Summary box:**

##### 135 **What is already known in this topic:**

- 136 • COVID-19 was declared a pandemic by the World Health Organization on March 11, 2020.
- 137 • Many observational studies have separately dealt with different clinical and epidemiologic  
138 features of this new and rapidly evolving disease.
- 139 • Very few systematic reviews about COVID-19 have been done and there was still a need  
140 for a systematic review and meta-analysis related to the clinical findings and the mortality  
141 of the disease in order to have a better understanding of COVID-19.
- 142 • Previous reports have indicated that older age and presence of multiple comorbidities are  
143 associated with increased mortality.

##### 144 **What this study adds:**



145       • The mortality rate in our study for hospitalized COVID-19 patients was 6.6% and males  
146           had around 3-fold higher risk of mortality compared to females (OR 3.4; 95% CI 1.2-9.1,  
147           P=0.01).

148       • These findings could indicate the need for more aggressive treatment of COVID-19 in  
149           males.

150

151

152

153

154

155

156

157

158

159

160

161

162 **Introduction**

163 Facing an immediate crisis by the novel coronavirus, Severe Acute Respiratory Syndrome  
164 Coronavirus 2, (SARS-CoV-2), which has been called the once in a century pathogen requires a  
165 global response to this outbreak(1). The disease caused by this virus has been named  
166 “coronavirus disease 2019” (COVID-19) by the World Health Organization. As of now, more than  
167 168 countries have reported COVID19 patients. Given the increasing number of countries infected  
168 with SARS-CoV-2, WHO declared COVID19 a pandemic on March 11, 2020.(2) The SARS-CoV-  
169 2 virus is a betacoronavirus and like the Middle East Respiratory Syndrome virus (MERS-CoV)  
170 and SARS-CoV that caused the previous respiratory syndrome outbreaks, belongs to the family  
171 of coronaviruses. However, this is the first pandemic caused by a member of the coronavirus  
172 family (3).

173

174 COVID19 started in China in December 2019 when a cluster of patients with pneumonia of  
175 unknown cause was identified in the city of Wuhan. Since then, it has infected hundreds of  
176 thousands of people around the world and resulted in more than 13000 deaths up to this date (4).  
177 Despite governmental travel restrictions in many countries, the confirmed number of new cases  
178 has been rising globally. The international community has asked for at least US\$675 million for  
179 preparedness and protection of states with weaker health systems (5).

180

181 In the previous two outbreaks of coronaviral respiratory illness, namely Severe Acute Respiratory  
182 Illness (SARS) and Middle East Respiratory Illness (MERS), gender-based difference in mortality  
183 was observed. In SARS, younger males were at twice the risk of death compared to females and  
184 the difference in mortality reduced with older age(6). The case fatality rate observed in males was  
185 twice that of females in MERS (7). The effect of sex on COVID-19 mortality was unknown. We  
186 evaluated this risk for COVID-19 patients as well.

187  
188 The novelty of COVID19 has raised many questions about the epidemiology of the disease,  
189 clinical and laboratory methods of diagnosis as well as therapeutic measures. Thus far, many  
190 observational studies have been dealing with these features separately, however, there is still a  
191 necessity for more systematic reviews specially to understand role of the sex in mortality of  
192 COVID19. In this meta-analysis study, we reviewed the published literature from January 1, 2019  
193 to March 3, 2020 to provide an overview for a better understanding of COVID-19.

194

## 195 **Methods**

### 196 *Search strategy*

197 We searched Pubmed/Medline, Embase, Web of Science and the Cochrane Library for studies  
198 published from January 1, 2019 to March 3, 2020. The search strategy was based on the following  
199 key-words: COVID-19, severe acute respiratory syndrome coronavirus 2, novel coronavirus,  
200 SARS-CoV-2, nCoV disease, SARS2, COVID19, Wuhan coronavirus, Wuhan seafood market

201 pneumonia virus, 2019-nCoV, coronavirus disease-19, coronavirus disease 2019, 2019 novel  
202 coronavirus and Wuhan pneumonia. Lists of references of selected articles and relevant review  
203 articles were hand-searched to identify further studies. This study was conducted and reported  
204 according to the PRISMA guidelines (8). The study did not require any ethics committee approval.  
205 This research was done without patient involvement. Patients were not invited to comment on the  
206 study design and were not consulted to develop patient relevant outcomes or interpret the results.  
207 Patients were not invited to contribute to the writing or editing of this document for readability or  
208 accuracy.

#### 209 *Study Selection*

210 The records found through database searching were merged and the duplicates were removed  
211 using EndNote X7 (Thomson Reuters, New York, NY, USA). Two reviewers (YF and PJ)  
212 independently screened the records by title and abstract to exclude those not related to the current  
213 study. The full texts of potentially eligible records were retrieved and evaluated by a third reviewer  
214 (AT). Included studies met the following inclusion criteria: (i) patients were confirmed and  
215 diagnosed with RT-PCR as suggested by WHO; (ii) The raw data for clinical, radiological and  
216 laboratory findings were included; and (iii) the outcomes were addressed. Studies with insufficient  
217 information about patients' characteristics and outcomes were excluded. Case reports, reviews,  
218 and animal studies were also excluded. Only studies written in English were selected.

#### 219 *Data extraction and quality assessment*

220 A data extraction form was designed by two reviewers (AZ and SH). These reviewers extracted  
221 the data from all eligible studies and differences were resolved by consensus. The following data  
222 were extracted: first author name; year of publication; type of study, country/ies where the study  
223 was conducted; distribution of age and sex in the population, number of patients investigated,  
224 data for clinical, radiological and laboratory findings, and outcomes.

### 225 *Data Synthesis and Analysis*

226 Statistical analyses were performed with STATA (version 14, IC; Stata Corporation, College  
227 Station, TX, USA). The pooled frequency with 95% confidence intervals (CI) was assessed using  
228 random effect model. The between-study heterogeneity was assessed by Cochran's Q and the  
229 I<sup>2</sup> statistic. Publication bias was assessed statistically by using Begg's and Egger's tests ( $p < 0.05$   
230 was considered indicative of statistically significant publication bias).

### 231 *Quality assessment*

232 The checklist provided by the Joanna Briggs Institute (JBI) was used to perform quality  
233 assessment(9).

234

## 235 **Results**

236 The search yielded 1102 publications, of which 259 potentially eligible studies were identified for  
237 full-text review, resulting in 32 studies fulfilling the inclusion criteria (Figure 1) (Table1). The mean

238 age of the patients was 49.0 years and 4789 patients were included. Based on JBI tool, the  
239 included studies had a low risk of bias.

#### 240 *Clinical manifestations*

241 The most common signs and symptoms were fever (83.0%, CI 77.5-87.6), cough (65.2%, CI 58.6-  
242 71.2), dyspnea (27.4%, CI 19.6-35.2), myalgia/fatigue (34.7, CI 26.0-44.4) followed by hemoptysis  
243 (2.4%, CI 0.8-6.7), diarrhea (5.7%, CI 3.8-8.6) and nausea/vomiting (5.0 %, CI 2.3-10.7). Sputum  
244 production (17.2%, CI 10.8-26.4) was a relatively common symptom. (Table 2).

#### 245 *Comorbidities*

246 The most common comorbidities were respectively hypertension (18.5 %, CI 12.7-24.4),  
247 cardiovascular diseases (14.9 %, CI 6.0-23.8), diabetes (10.8 %, CI 8.3-13.3), chronic liver  
248 disease (8.1, CI 4.6-11.6) and smoking (8.0%, CI 2.3-13.6) (Table 3).

#### 249 *Laboratory findings*

250 The most frequent abnormal laboratory findings in patients with COVID-19 were respectively,  
251 increased C-Reactive Protein (CRP) (72% CI 54.3-84.6), lymphopenia (50.1%, CI 38.0-62.4), high  
252 levels of Lactate Dehydrogenase (LDH) (41%,CI 22.8-62.0), increased serum aspartate  
253 aminotransferase (19.7%, CI 10.5-33.7) and thrombocytopenia (11.1%, CI 7.7-15.7) (Table 4).  
254 Among the confirmed COVID19 subjects, 14.0% (CI, 6.7-29.0) had viremia. Impaired hepatic  
255 function with ALT levels greater than 47.25 U/L was seen in 13.3% (CI 3.2-41.0) of COVID19  
256 subjects. Acute cardiac injury with troponin levels greater than 28 pg/ml was seen in 12.4% of

257 the patients. Acute kidney injury was found in 5.5% (CI 1.3-20.8). Shock was reported in 4.0% (CI  
258 1.6-12.0) shock. 13.0% (CI 4.8-30.0) met the definition of acute respiratory distress syndrome  
259 (ARDS).

#### 260 *Radiologic findings*

261 Chest X-Ray (CXR) and chest CT-scan were the common imaging modalities used for the  
262 diagnosis of COVID19. The pooled sensitivity for CT-scan for COVID19 was 79.3%. The most  
263 common sites of the lung involvement based on chest CT-scan were right lower lobe (76.2, CI  
264 57.8-82.5) followed by left lower lobe (71.8%, CI 57.8-82.5). Most of the patients (74.8%) had  
265 bilateral involvement. The most common pattern of parenchymal involvement was ground-glass  
266 opacity (66.0%, CI 51.1-78.0). The chest CT-scan was reported normal in 20.7% of the patients  
267 with confirmed RT-PCR results (Table 5).

#### 268 *Outcomes*

269 Hospitalization was required in 94.6% of patients with severe COVID-19. The pooled mortality  
270 rate of these patients was about 6.6% (CI 2.8-15.0) (Table 6, 7). Old age, male sex, presence of  
271 underlying diseases, higher level of D-dimer, lower level of fibrinogen and anti-thrombin,  
272 progressive radiographic deterioration in follow up CT-scans, developed ARDS and requirement  
273 of mechanical ventilation were reported factors associated with increased mortality rate. As shown  
274 in Table 8, men had significantly higher mortality in the hospital compared to women (OR 3.4;  
275 95% CI 1.2-9.1, P=0.01). Although ICU admission was higher in men, the difference was not  
276 significant. The mean duration between the time of hospitalization and death was 17.5 days with

277 minimum and maximum periods of 14 and 21 days respectively. The effects and summaries  
278 calculated using a random-effects model weighted by the study population is shown in Figure 2.

279

280

## 281 **Discussion**

282 We evaluated the signs and symptoms, diagnostic modalities, therapeutic measures and  
283 epidemiologic features of COVID-19 to have a better understanding of this pandemic caused by  
284 SARS-CoV-2. In terms of clinical manifestations, the most common signs and symptoms were  
285 fever and cough. Hypertension and cardiovascular diseases were the most common  
286 comorbidities among patients. Between the different abnormal laboratory findings, increased  
287 levels of CRP and lymphopenia were the most common findings. Chest X-Ray and chest CT-scan  
288 were the most common imaging modalities used for the diagnosis. The pooled sensitivity of CT-  
289 scan for COVID19 was 79.3%. We found 20.7% of the patients with confirmed RT-PCR who had  
290 normal chest CT-Scan suggesting that a normal chest CT-scan cannot rule out the disease in  
291 patients who are highly suspicious for COVID-19. Several complications were seen due to  
292 COVID-19. Among these, acute hepatitis was the most common one occurring in 13.3% of cases,  
293 followed by cardiac injury with troponin levels greater than 28 pg/ml seen in 12.4%. The pooled  
294 mortality rate of these patients was 6.6%. We detected several factors contributing to a worse  
295 outcome including old age, male sex, presence of underlying diseases and some abnormal  
296 laboratory finding such as high level of D-Dimer. Although there was not any significant difference



297 between male and female gender in ICU admissions, male gender showed a significantly higher  
298 in-hospital mortality rate.

299  
300 The current study showed that fever (83.0%), cough (65.2%) and dyspnea (27.4%) were the most  
301 common signs and symptoms. In a study done by Zhang et al in Wuhan, fever was identified as  
302 the most common clinical finding present in 91.7% of the patients followed by cough in 75% of  
303 patients. Their study showed a higher gastrointestinal (GI) manifestation at presentation of the  
304 disease, representing 39.6% of the patients (10). Our study showed a lower prevalence of GI  
305 symptoms including diarrhea, which was present in 5.7% of patients and nausea/vomiting in 5%.

306  
307 The most prevalent comorbidities in our study were hypertension (18.5 %, CI 12.7-24.4) followed  
308 by cardiovascular diseases (14.9 %, CI 6.0-23.8) and diabetes (10.8 %, CI 8.3-13.3). According  
309 to a systematic review for comorbidities by Yang et al, hypertension ( $17 \pm 7\%$ , CI 14-22%) and  
310 diabetes ( $8 \pm 6\%$ , CI 6-11%), followed by cardiovascular diseases ( $5 \pm 4\%$ , CI 4-7%) were the  
311 most common comorbid findings (11). The high prevalence of hypertension and other  
312 cardiovascular comorbidities have raised speculation regarding the role of angiotensin-converting  
313 enzyme Inhibitors (ACEI) in COVID-19. Angiotensin-converting enzyme 2 (ACE2) receptor has  
314 been identified as the receptor used by SARS-CoV-2 to infect human cells and previous studies  
315 have shown that the usage of ACEI results in the upregulation of ACE2 (12) (13). Theoretically,  
316 this increase in ACE2 levels could result in a greater risk of infection with the SARS-CoV-2 virus.

317 Current evidence against the use of ACEI in patients with COVID-19 or those at risk of the disease  
318 is limited, and further studies are needed to analyze this possible association.

319

320 The most common laboratory abnormalities were elevated C-Reactive Protein (CRP) (72%),  
321 lymphopenia (50.1%) and elevated LDH (41%). Also, thrombocytopenia was seen in 11.1% of  
322 the subjects. Analyses by Huang et al and Lippi et al have suggested that lymphopenia and  
323 thrombocytopenia in COVID-19 patients are associated with poorer outcomes, respectively (14,  
324 15). Interestingly, patients with SARS were reported to have a higher percentage of lymphopenia  
325 (68-90%) and thrombocytopenia (20-45%) compared to COVID-19 patients (16). A similar  
326 reduction in counts was also observed in patients with H1N1 influenza (17). Thrombocytopenia  
327 and lymphopenia have been previously shown to strongly indicate a higher risk of mortality in  
328 SARS and influenza (17, 18). Given the current lack of predictive biomarkers in COVID-19,  
329 lymphocyte and platelet count may be used as indicators of severe disease in the clinical setting.

330

331 Liver abnormality was the most common complication and was present among 13.3% of the  
332 subjects, although the data was reported only in 3 studies. However, a significant number of  
333 subjects had elevated AST (19.7%) and ALT (14.6%). Impaired liver function has been observed  
334 as collateral damage in some viral infections including SARS, possibly caused by direct damage  
335 to the hepatic tissue by the pathogen (19). While this could be the case with COVID19, an  
336 iatrogenic effect due to medications like lopinavir cannot be ruled out.

337

338 Another significant finding in our analysis was the incidence of cardiac injury in 12.4% of the  
339 patients, which is a common event seen in a multitude of viral illnesses(20). Gao et al observed  
340 that subjects with influenza (H7N9) and cardiac injury had an elevated risk of mortality (HR=2.06)  
341 (21). In a study by Ludwig et al for analysis of cardiac biomarkers in influenza patients, 24% of  
342 the subjects showed ACI in  $\leq 30$  days after influenza diagnosis and half of them were myocardial  
343 infarction (22). Although our analysis did not show increased mortality risk in patients with cardiac  
344 injury, these findings could indicate the potential need for identifying and optimizing cardiac risk  
345 factors in COVID-19 patients during the treatment period.

346

347 The mean duration between hospitalization and death was 17.5 days (range- 14-21 days),  
348 compared to 17.4 days in SARS (23). The overall mortality rate in this study was 6.6%, which is  
349 more than twice than previously reported (24). Though comparable mortality was reported by Li  
350 et al (7%) and Qian et al (8.9%) in their meta-analyses, a study by Rodriguez et al showed a much  
351 higher death rate of 13.9% (25-27). On the other hand, a study from the Jiangsu province of China  
352 results showed a high cure rate equal to 96.67%. Although the main reason for very low mortality  
353 on this study remains unknown, measures including early recognition and centered-quarantine  
354 may be contributing factors(28).

355

356 Of note, the in-hospital mortality of males was significantly higher than females (OR 3.4; 95% CI  
357 1.2-9.1,  $P=0.01$ ). A similar pattern of higher mortality in males has been reported in previous  
358 coronavirus outbreaks of SARS and MERS. Karlberg et al also reported that the gender-based

359 difference in mortality was higher in younger males (0-44 years) (RR=2), compared to those of  
360 age group 45-74 (RR-1.45) (6). Similarly, the study by Alghamdi et al showed that the case fatality  
361 rate in males was twice that of females in MERS (52% VS 23%) (29). Although a gender-based  
362 difference in the immune response to infections has been suggested as a possible factor, other  
363 contributing factors including smoking history and severity of underlying comorbidities cannot be  
364 ruled out (30). This is especially of significance in China, where the prevalence of smoking among  
365 men (57.6%) is almost 10 times higher than in women (6.7%) (31). This difference in mortality  
366 opens the discussion for the need to treat COVID19 more aggressively in males, including the  
367 possibility of earlier intubation and mechanical ventilation in this population. Further investigations  
368 are also needed to understand this phenomenon.

369  
370 This study has several limitations. Due to the rapidly emerging COVID-19 situation around the  
371 globe and the novelty of this coronavirus, there is still limited clinical data regarding diagnostic  
372 modalities and effective therapeutic measures. Most of the clinical findings were from  
373 observational studies. Future clinical trials and animal models are also required to have  
374 conclusive clinical information. We also need more studies outside of China for a comprehensive  
375 result that reflects COVID-19 globally. In the end, due to the lack of accurate reports of the new  
376 cases in different countries, the epidemiologic measures are also limited. As this pandemic is  
377 growing fast, future studies are needed for the evaluation of epidemiologic and clinical features  
378 of COVID-19.

379

380 **Conclusion:**

381 COVID-19 presents with a significant number of mortalities especially among males around the  
382 world. The pooled mortality rate in our study was 6.6%. The high rate of hospitalization and case  
383 fatality among hospitalized patients along with the lack of intensive care facilities necessitated the  
384 identification of factors associated with the severe disease and mortality. These factors included  
385 male gender, age, underlying diseases, higher level of D-Dimer, lower level of fibrinogen and anti-  
386 thrombin, progressive radiographic deterioration on follow up, developed ARDS and requirement  
387 of mechanical ventilation. It was inferred that higher comorbidities such as hypertension and  
388 cardiovascular diseases could be related to the pathogenesis of the virus through ACE II receptor.  
389 This association could open doors for future studies to evaluate the role of ACE inhibitor drugs in  
390 the high-risk group. There are still a lot of unknown features of COVID-19 for the broad scientific  
391 community to investigate in an effort to slow the progression and mortality of COVID-19 and finally  
392 defeat this pandemic.

393

394

## References:

1. Gates B. Responding to Covid-19 — A Once-in-a-Century Pandemic? *New England Journal of Medicine*. 2020.
2. Coronavirus disease 2019 (COVID-19) situation summary: Center for Disease Control and Prevention  
2020 [cited 2020 3/12/2020]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/summary.html>.
3. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? *International Journal of Epidemiology*. 2020.
4. Lukelsu. Coronavirus Dashboard (GEOG 4046 example) 2020 [Available from: <https://www.arcgis.com/apps/opsdashboard/index.html#/90b89509931e4c309e83d7f51e101a08>].
5. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*. 2020.
6. Karlberg J, Chong DS, Lai WY. Do men have a higher case fatality rate of severe acute respiratory syndrome than women do? *Am J Epidemiol*. 2004;159(3):229-31.
7. Alghamdi IG, Hussain, II, Almalki SS, Alghamdi MS, Alghamdi MM, El-Sheemy MA. The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health. *Int J Gen Med*. 2014;7:417-23.
8. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Annals of internal medicine*. 2009;151(4):264-9.
9. Munn Z, Moola S, Lisy K, Riitano D. The Joanna Briggs institute reviewers' manual 2014. The systematic review of prevalence and incidence data Adelaide: The Joanna Briggs Institute. 2014.
10. Zhang Jj, Dong X, Cao YY, Yuan Yd, Yang Yb, Yan Yq, et al. Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China. *Allergy*. 2020.
11. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. *Int J Infect Dis*. 2020.
12. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Medicine*. 2020.
13. Tikellis C, Thomas MC. Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. *Int J Pept*. 2012;2012:256294.
14. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
15. Lippi G, Plebani M, Michael Henry B. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. *Clin Chim Acta*. 2020.
16. Yang M, Hon KL, Li K, Fok TF, Li CK. The effect of SARS coronavirus on blood system: its clinical findings and the pathophysiologic hypothesis. *Zhongguo Shi Yan Xue Ye Xue Za Zhi*. 2003;11(3):217-21.
17. Lopez-Delgado JC, Rovira A, Esteve F, Rico N, Manez Mendiluce R, Ballus Noguera J, et al. Thrombocytopenia as a mortality risk factor in acute respiratory failure in H1N1 influenza. *Swiss Med Wkly*. 2013;143:w13788.
18. Bellelli V, d'Ettorre G, Celani L, Borrazzo C, Ceccarelli G, Venditti M. Clinical significance of lymphocytopenia in patients hospitalized with pneumonia caused by influenza virus. *Critical Care*. 2019;23(1):330.

19. Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam LYC, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. *The Lancet*. 2003;361(9366):1319-25.
20. Greaves K, Oxford JS, Price CP, Clarke GH, Crake T. The Prevalence of Myocarditis and Skeletal Muscle Injury During Acute Viral Infection in Adults: Measurement of Cardiac Troponins I and T in 152 Patients With Acute Influenza Infection. *Archives of Internal Medicine*. 2003;163(2):165-8.
21. Gao C, Wang Y, Gu X, Shen X, Zhou D, Zhou S, et al. Association Between Cardiac Injury and Mortality in Hospitalized Patients Infected With Avian Influenza A (H7N9) Virus. Read Online: *Critical Care Medicine | Society of Critical Care Medicine*. 2020;48(4):451-8.
22. Ludwig A, Lucero-Obusan C, Schirmer P, Winston C, Holodniy M. Acute cardiac injury events  $\leq$ 30 days after laboratory-confirmed influenza virus infection among U.S. veterans, 2010-2012. *BMC Cardiovasc Disord*. 2015;15:109.
23. Feng D, Jia N, Fang L-Q, Richardus JH, Han X-N, Cao W-C, et al. Duration of symptom onset to hospital admission and admission to discharge or death in SARS in mainland China: a descriptive study. *Tropical Medicine & International Health*. 2009;14(s1):28-35.
24. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of Medicine*. 2020.
25. Qian K, Deng Y, Tai Y, Peng J, Peng H, Jiang L. Clinical Characteristics of 2019 Novel Infected Coronavirus Pneumonia : A Systemic Review and Meta-analysis. *medRxiv*. 2020:2020.02.14.20021535.
26. Li L-q, Huang T, Wang Y-q, Wang Z-p, Liang Y, Huang T-b, et al. 2019 novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of meta-analysis. *Journal of Medical Virology*.n/a(n/a).
27. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. *Travel Medicine and Infectious Disease*. 2020:101623.
28. Sun Q, Qiu H, Huang M, Yang Y. Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province. *Annals of Intensive Care*. 2020;10(1):33.
29. Alghamdi IG, Hussain II, Almalki SS, Alghamdi MS, Alghamdi MM, El-Sheemy MA. The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health. *Int J Gen Med*. 2014;7:417-23.
30. Klein SL. The effects of hormones on sex differences in infection: from genes to behavior. *Neuroscience & Biobehavioral Reviews*. 2000;24(6):627-38.
31. Yang T, Barnett R, Jiang S, Yu L, Xian H, Ying J, et al. Gender balance and its impact on male and female smoking rates in Chinese cities. *Social Science & Medicine*. 2016;154:9-17.
32. Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. *International Journal of Infectious Diseases*. 2020;91:264-6.
33. Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. *Journal of Medical Virology*. 2020.
34. Xu X-W, Wu X-X, Jiang X-G, Xu K-J, Ying L-J, Ma C-L, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *Bmj*. 2020;368.
35. Zhang W, Du R-H, Li B, Zheng X-S, Yang X-L, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. *Emerging microbes & infections*. 2020;9(1):386-9.
36. To KK-W, Tsang OTY, Chik-Yan Yip C, Chan K-H, Wu T-C, Chan J, et al. Consistent detection of 2019 novel coronavirus in saliva. *Clinical Infectious Diseases*. 2020.
37. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. *New England Journal of Medicine*. 2020.



38. Hoehl S, Berger A, Kortenbusch M, Cinatl J, Bojkova D, Rabenau H, et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. *New England Journal of Medicine*. 2020.
39. Pan Y, Zhang D, Yang P, Poon LL, Wang Q. Viral load of SARS-CoV-2 in clinical samples. *The Lancet Infectious Diseases*. 2020.
40. Tang N, Li D, Wang X, Sun Z. Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *Journal of Thrombosis and Haemostasis*. 2020.
41. Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). *Radiology*. 2020:200230.
42. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. *Radiology*. 2020:200432.
43. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. *New England Journal of Medicine*. 2020.
44. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020;395(10223):497-506.
45. Kui L, Fang Y-Y, Deng Y, Liu W, Wang M-F, Ma J-P, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chinese medical journal*. 2020.
46. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. *New England Journal of Medicine*. 2020.
47. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Science China Life Sciences*. 2020:1-11.
48. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. *Jama*. 2020.
49. Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study. *Clinical Infectious Diseases*. 2020.
50. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases. *Radiology*. 2020:200642.
51. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. *Radiology*. 2020:200370.
52. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *New England Journal of Medicine*. 2020;382(8):727-33.
53. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet Respiratory Medicine*. 2020.
54. Bajema KL, Oster AM, McGovern OL, Lindstrom S, Stenger MR, Anderson TC, et al. Persons Evaluated for 2019 Novel Coronavirus—United States, January 2020. *Morbidity and Mortality Weekly Report*. 2020;69(6):166.
55. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT findings in coronavirus disease-19 (COVID-19): Relationship to duration of infection. *Radiology*. 2020:200463.
56. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet*. 2020;395(10223):507-13.
57. Pan Y, Guan H, Zhou S, Wang Y, Li Q, Zhu T, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. *European radiology*. 2020:1-4.
58. Xu Y-H, Dong J-H, An W-m, Lv X-Y, Yin X-P, Zhang J-Z, et al. Clinical and computed tomographic imaging features of Novel Coronavirus Pneumonia caused by SARS-CoV-2. *Journal of Infection*. 2020.



59. Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. *European Journal of Nuclear Medicine and Molecular Imaging*. 2020:1-6.
60. Chang D, Lin M, Wei L, Xie L, Zhu G, Cruz CSD, et al. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. *Jama*. 2020.
61. Chen W, Lan Y, Yuan X, Deng X, Li Y, Cai X, et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. *Emerging Microbes & Infections*. 2020;9(1):469-73.
62. Kwok KO, Wong V, Wei VWI, Wong SYS, Tang JW-T. Novel coronavirus (2019-nCoV) cases in Hong Kong and implications for further spread. *Journal of Infection*. 2020.

**Tables:**

**Table1. Characteristics of the included studies**

<b>First Author</b>	<b>Country</b>	<b>Published time</b>	<b>Type of study</b>	<b>Mean age</b>	<b>Male/Female</b>	<b>Nationality</b>	<b>No. of patients</b>	<b>Diagnostic methods</b>
S. Hui(32)	China	14, Jan, 2020	Case series	NR	NR	Chinese	41	RT-PCR/CT-scan
Xia(33)	China	26, Feb, 2020	Case series	54.5	21M, 9F	Chinese	30	RT-PCR
Wei Xu(34)	China	13, Feb, 2020	Case series	41	M35, F27	Chinese	62	RT-PCR
Wei Zhang(35)	China	7, Feb, 2020	Case series	NR	NR	Chinese	178	RT-PCR
Kai-Wang To(36)	China	12, Feb, 2020	Case series	62.5	7M, 5F	Chinese	12	RT-PCR
Zou(37)	China	19, Feb, 2020	Correspondence	59	9M ,9F	Chinese	18	RT-PCR
Hoehl(38)	Germany	3, Mar, 2020	Correspondence	35	NR	German	126	RT-PCR/CT-scan
Yang Pan(39)	China	24, Feb, 2020	Correspondence	NR	NR	Chinese	82	RT-PCR/CT-scan
Tang(40)	China	19, Feb, 2020	Cross-sectional	54	98M, 85F	Chinese	183	RT-PCR
Chung(41)	China	4, Feb, 2020	Cross-sectional	51	M13, F8	Chinese	21	RT-PCR/CT-scan
Yicheng Fang2(42)	China	19, Feb, 2020	Cross-sectional	45	29M, 22F	Chinese	51	RT-PCR/CT-scan
Guan(43)	China	28, Feb, 2020	Cross-sectional	47	640M,459F	Chinese	1099	RT-PCR/CT-scan
Huang(44)	China	24, Jan, 2020	Cross-sectional	49	30M,11F	Chinese	41	RT-PCR
Kui Liu(45)	China	7, Feb, 2020	Cross-sectional	57	61M,76F	Chinese	137	RT-PCR
Qun Li(46)	China	29, Jan, 2020	Cross-sectional	52	M238, F187	Chinese	425	RT-PCR/CT-scan

Yingxia Liu(47)	China	9, Feb, 2020	Cross-sectional	53.6	8M, 4F	Chinese	12	RT-PCR/CT-scan
Dawei Wang(48)	China	7, Feb, 2020	Cross-sectional	56	75M , 63F	Chinese	138	RT-PCR/CT-scan
Jian Wu(49)	China	29, Feb, 2020	Cross-sectional	46	39M, 41F	Chinese	80	RT-PCR
Jin-jin Zhang(10)	China	19, Feb, 2020	Cross-sectional	57	71M,69F	Chinese	140	RT-PCR
Ai(50)	China	26, Feb, 2020	Cross-sectional	48.5	M467, F547	Chinese	1014	RT-PCR/CT scan
Feng Pan(51)	China	13, Feb, 2020	Cross-sectional	40	6M, 15F	Chinese	21	RT-PCR/CT-scan
Heshui Shi2(52)	China	24, Feb, 2020	Cross-sectional	49.5	42M, 39F	Chinese	81	RT-PCR/CT-scan
Yang(53)	China	21, Feb, 2020	Cross-sectional	59.7	35M, 17F	Chinese	52	RT-PCR
Bajema(54)	China	4, Feb, 2020	Cross-sectional	NR	115M, 95F	Chinese	210	RT-PCR/CT-scan
Bernheim(55)	China	20, Feb, 2020	Cross-sectional	45.3	61M, 60F	Chinese	121	RT-PCR
Nanshan Chen(56)	China	15, Feb, 2020	Cross-sectional	55.5	67M, 32F	Chinese	99	RT-PCR
Yueying Pan(57)	China	13, Feb, 2020	Cross-sectional	45	33M, 30F	Chinese	63	RT-PCR
Yu-Huan Xu(58)	China	21, Feb, 2020	Cross-sectional	44	29M, 21F	Chinese	50	RT-PCR/CT-scan
Xi Xu(59)	China	28, Feb, 2020	Cross-sectional	50	39M, 51F	Chinese	90	RT-PCR
De Chang(60)	China	7, Feb, 2020	Research letter	34	10M, 3F	Chinese	13	RT-PCR/CT-scan
Weilie Chen(61)	China	26, Feb, 2020	Research letter	NR	NR	Chinese	85	RT-PCR/CT-scan
Kwok(62)	China	7, Feb, 2020	Research letter	59.8	9M, 5F	Chinese	14	RT-PCR/CT-scan

**Table 2. Meta-analysis of comorbidities**

	Number of studies	Pooled frequency (95% CI)	n/N*	Publication bias (p value)	Heterogeneity test	
					I <sup>2</sup> (%)	p value
Smoking	4	8.0 (2.3-13.6)	172/1332	0.06	100	0.00
Hypertension	9	18.5 (12.7-24.4)	306/1800	0.98	100	0.00
Cardiovascular disease	12	14.9 (6.0-23.8)	178/2031	0.72	100	0.00
Diabetes	11	10.8 (8.3-13.3)	166/1932	0.39	100	0.00
Pulmonary disease	12	3.4 (0.8-6.0)	39/2031	0.72	100	0.00
Malignancies	9	2.8 (0.8-4.8)	33/1816	0.74	100	0.00
Chronic liver disease	7	8.1 (4.6-11.6)	29/546	0.45	100	0.00
Renal disease	6	4.4 (0.24-8.6)	17/1472	0.33	100	0.00

\*n, number of patients with comorbidity; N, total number of patients.

**Table 3. Meta-analysis of clinical manifestations**

	Number of studies	Pooled frequency (95% CI)	n/N*	Publication bias (p value)	Heterogeneity test	
					I <sup>2</sup> (%)	p value
Fever	21	83.0 (77.5-87.6)	2073/2465	0.76	86	0.00
Cough	22	65.2 (58.6-71.2)	1689/2515	0.80	85	0.00
Dyspnea	13	27.4 (19.6-35.2)	477/2014	0.42	89	0.00
Myalgia/fatigue	17	34.7 (26.0-44.4)	742/1938	0.60	89	0.00
Sputum production	12	17.2 (10.8-26.4)	480/1862	0.01	89	0.00
Sore throat	7	14.5 (10.6-19.5)	224/1577	0.88	66	0.00
Headache	12	11.1 (7.7-15.7)	230/1864	0.30	74	0.00
Diarrhea	13	5.7 (3.8-8.6)	104/2041	0.77	66	0.00
Hemoptysis	4	2.4 (0.8-6.7)	20/1339	0.77	100	0.00
Anorexia	4	10.1 (1.0-57.2)	82/1322	0.73	98	0.00
Nausea/vomiting	7	5.0 (2.3-10.7)	65/1563	0.90	85	0.00
Dizziness	3	8.6 (2.5-26.0)	16/205	0.90	65	0.00
Chest tightness	5	8.4 (2.5-26.0)	24/256	0.24	78	0.00
Rhinorrhea	3	9.3 (2.2-31.0)	28/232	0.17	88	0.00
Chills	2	14.3 (3.0-47.4)	12/111	NA	86	0.00

**Table 4. Meta-analysis of laboratory findings**

	Number of studies	Pooled frequency (95% CI)	n/N*	Publication bias (p value)	Heterogeneity test	
					I <sup>2</sup> (%)	p value
Lymphopenia	11	50.1 (38.0-62.4)	1122/1853	0.08	93	0.00
Lymphocytosis	2	33.5 (2.4-90.2)	55/93	NA	88	0.00
Neutrophilia	3	29.7 (19.3-42.7)	60/191	0.51	58.7	0.08
Leukopenia	9	28.0 (20.0-37.4)	544/1798	0.89	88	0.00
Leukocytosis	9	10.8 (5.8-19.1)	165/1829	0.86	92	0.00
Thrombocytopenia	6	11.1 (7.7-15.7)	343/1393	0.00	86	0.00
Anemia	2	43.5 (30.3-57.7)	79/179	NA	72	0.00
Decreased Albumin	3	51.8 (2.0-98.0)	105/191	0.99	96	0.00
High CRP	8	72.0 (54.3-84.6)	918/1681	0.02	96	0.00
High LDH	6	41.0 (22.8-62.0)	408/1393	0.32	94	0.00
High ESR	2	79.7 (66.6-88.5)	143/179	NA	69	0.00
High AST	7	19.7 (10.5-33.7)	267/1474	0.70	93	0.00
High ALT	4	14.6 (7.6-26.3)	191/1290	0.99	84.8	0.00
High Creatinine Kinase	7	14.1 (8.3-23.0)	142/1453	0.20	84	0.00
High Bilirubin	3	7.9 (2.9-19.0)	95/1278	0.96	89	0.00
High Creatinine	5	3.3 (1.2-9.1)	20/1294	0.13	74	0.00
High Troponin I	1	2.4 (0.3-15.0)	1/41	NA	0.00	0.1

**Table 5. Meta-analysis of imaging findings**

CT Scan	Patterns		Number of studies	Pooled frequency (95% CI)	n/N*	Publication bias (p value)	Heterogeneity test	
							I <sup>2</sup> (%)	p value
Location of involvement	Number of affected lobe	Unaffected	3	20.7 (15.1-27.6)	33/161	0.18	0.0	0.57
		1 lobe	5	14.8 (7.4-24.0)	52/318	0.22	73	0.00
		2 lobes	5	9.5 (6.5-12.8)	30/318	0.32	0.0	0.50
		3 lobes	5	11.7 (7.9-14.6)	36/318	0.64	0.0	0.50
		4 lobes	5	15.8 (10.3-20.7)	49/318	0.90	40	0.15
		5 lobes	5	37.2 (32.0-42.3)	118/318	0.50	30	0.22
	Affected lobe (s)	RUL	4	56.8 (50.6-62.8)	145/255	0.12	52	0.10
		RML	4	48.6 (42.5-54.8)	124/255	0.07	0.0	0.48
		RLL	4	76.2 (65.5-84.4)	193/255	0.14	64	0.03
		LUL	4	56.0 (47.1-64.7)	153/255	0.12	0.0	0.40
		LLL	3	71.8 (57.8-82.5)	167/234	0.30	76	0.01
	Laterality	Uni lateral	3	28.8 (16.6-45.2)	62/205	0.80	77	0.01
		Bi lateral	3	70.6 (55.3-82.5)	142/205	0.20	74	0.01
Pattern of involvement	Pattern of involvement	No involvement	4	17.2 (11.4-25.0)	193/1080	0.42	63.0	0.04
		Both of GGO* & Consolidation	2	39.0 (28.1-51.0)	57/142	NA	25	0.24
		GGO without consolidation	10	66.0 (51.1-78.0)	846/1365	0.67	90	0.00
		Consolidation without GGO	3	9.4 (3.3-23.6)	26/274	0.21	82	0.00
	Laterality	Uni lateral	7	21.8 (12.0-36.3)	101/507	0.63	87	0.00
		Bi lateral	8	74.8 (62.5-84.0)	405/548	0.29	84	0.00

\*GGO: Ground Glass Opacities

**Table 6. Meta-analysis of complications**

	Number of studies	Pooled frequency (95% CI)	n/N*	Publication bias (p value)	Heterogeneity test	
					I <sup>2</sup> (%)	p value
RNAemia	1	14.0 (6.7-29.0)	6/41	NA	0.00	1.00
ARDS	9	13.0 (4.8-30.0)	142/1794	0.67	96	0.00
Acute cardiac injury	4	12.4 (6.2-23.2)	28/243	0.83	65	0.03
Acute kidney injury	6	5.5 (1.3-20.8)	34/1441	0.58	93	0.00
Liver failure	3	13.3 (3.2-41.0)	20/144	0.50	84	0.00
Shock	5	4.0 (1.6-12.0)	32/1389	0.60	86	0.00
Hospitalization	10	94.6 (73.8-99.1)	1561/1829	0.76	98	0.00




**Table 7. Meta-analysis of outcomes**

	Number of studies	Pooled frequency (95% CI)	n/N*	Publication bias (p value)	Heterogeneity test	
					I <sup>2</sup> (%)	p value
Discharged	14	52.7 (36.5-68.4)	486/948	0.44	93	0.00
Death	11	6.6 (2.8-15.0)	111/2026	0.50	93	0.00


**Table 8. Mortality and ICU admission in men vs women in patients with COVID-19**

	Number of studies	Pooled OR (95% CI)	<i>p</i> value	Heterogeneity test	
				I <sup>2</sup> (%)	<i>p</i> value
Mortality in men vs women	2	3.4 (1.2-9.1)	0.01	0.00	0.6
ICU admission in men vs women	2	1.6 (0.7-3.2)	0.1	0.00	0.5

**Figures legends:**



**Figure1. Flow chart of study selection for inclusion in the systematic review and meta-analysis.**



**Figure 2. The pooled mortality rate of patients with COVID-19. Effects and summaries were calculated using a random-effects model weighted by study population.**

